An interventional study of Highlighting Patients at Risk for Sensory Screening (HPARSS) in Childhood Cancer, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Health services research
The overall goal of this study is to attempt to overcome the organizational barriers that impede prompt screening for at-risk sensory deficits in childhood cancer survivors (CCS). Using a cross sectional design study, collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the highlighting patients at risk for sensory screening (HPARSS) document. The investigators will utilize the HPARSS that will link therapy related risks for sensory deficits to specific screening procedures prompting the primary oncology provider to implement screening, diagnostic testing, and therapy.
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 146 is above the median of 60 across 7,703 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Washington University School of Medicine is the lead sponsor of 1,803 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
* The primary oncology team will utilize the HPARSS to identify patients who are at risk for sensory deficits based on prior treatment. The HPARSS will constitute a file of that will contain eligible patients based upon their past treatment and their corresponding risk for a particular sensory deficit based upon that treatment. The patient and parent/guardian will be approached to participate in the study. * Sensory deficit screening will be completed in the clinic and any screening results that indicate the need for referral for diagnostic testing or therapy will be scheduled by the primary treatment team staff.
Other: Highlighting Patients at Risk for Sensory Screening (HPARSS)
-Providers will complete a survey regarding their views of the HPARSS. The Acceptability of Intervention Measure has 4 questions and the Feasibility of Intervention Measure has 4 questions.
Collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the HPARSS document.
Percentage of patients with at risk for sensory deficits identified by HPARSS
Time frame: Through completion of enrollment for all patients (estimated to be 9 months)
Percentage of at risk patients who fail the assigned screening test
Time frame: Through completion of enrollment for all patients (estimated to be 9 months)
Percentage of patients in need of referral for screen test results who participate in formal diagnostic testing and/or treatment
Time frame: Through 1 year after the completion of screening test for all participants (estimated to be 1 year and 9 months)
Number and types of barriers to participation in formal diagnostic testing and therapy in CCS failing to engage in sensory screening
Time frame: At approximately 2 months following the patient's screening
Number and types of facilitators to participation in formal diagnostic testing and therapy in CCS failing to engage in sensory screening
Time frame: At approximately 2 months following the patient's screening
Acceptability of HPARSS as measured by the Acceptability of Intervention Measure (AIM)
-4 questions inquiring about the acceptability of HPARSS with answers ranging from completely disagree=1 to completely agree=5. The higher the score indicates higher acceptability of the HPARSS.
Time frame: To be completed at the time of enrollment completion (approximately 9 months)
Feasibility of intervention as measured by Feasibility of Intervention Measure (FIM)
-4 questions inquiring about the feasibility of HPARSS with answers ranging from completely disagree=1 to completely agree=5. The higher the score indicates higher feasibility of the HPARSS.
Time frame: To be completed at the time of enrollment completion (approximately 9 months)
Plan to share: No
Started Aug 2023 (actual). Primary completion is estimated for May 2027, 45 months after the start.
Of 1,981 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 45 months is above that.
Counting every sponsor, half of 2,056 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine →